NCT03162562 2020-12-22The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian CancerCanariaBio Inc.Phase 1 Terminated10 enrolled
NCT00034138 2007-12-18A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial CarcinomaUnither PharmaceuticalsPhase 1/2 Terminated24 enrolled
NCT00034372 2007-12-18Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian CarcinomaUnither PharmaceuticalsPhase 2 Terminated102 enrolled
NCT00050375 2007-12-18Clinical Trial for Ovarian Cancer (OvaRex®)Unither PharmaceuticalsPhase 3 Terminated354 enrolled
NCT00086632 2007-12-18Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer TreatmentUnither PharmaceuticalsPhase 2 Terminated40 enrolled